| Objectives:Compare the clinical efficacy and safety of Qili Qiangxin Capsules,Qishen Yiqi Dropping Pills,and Entresto in the treatment of heart failure(HFr EF)patients with reduced ejection fraction for 6 months,as well as the clinical efficacy of two medication methods in HFr EF caused by coronary heart disease and dilated cardiomyopathy.Methods:A retrospective analysis was conducted on the clinical data of 100 HFr EF patients diagnosed with HFr EF at Bethune Hospital in Shanxi Province from June 2021 to June2022,who were treated with Qili Qiangxin Capsules,Qishen Yiqi Dropping Pills,and Noxintuo.They were divided into Qili Qiangxin Group(50 cases)and Qishen Yiqi Group(50 cases).According to the different causes of heart failure,there were 34 cases in the coronary heart disease subgroup,55 cases in the dilated heart disease subgroup,and 11 cases in the heart failure caused by other causes.Among them,the coronary heart disease subgroup was divided into 16 cases in the Qili Qiangxin coronary heart disease subgroup and 18 cases in the Qishen Yiqi ischemic cardiomyopathy subgroup;The dilated heart disease subgroup was divided into the Qili Qiangxin group with 29 cases of dilated heart disease subgroup and the Qishen Yiqi dilated heart disease subgroup with 26 cases.Compare the efficacy and safety of two medication methods.Results:1.Comparison of general data between two groups: There was no statistically significant difference in gender,age,blood pressure,heart rate,NYHA cardiac function grading,past medical history,and medication use between the two groups of patients(P>0.05).2.Comparison of clinical efficacy between the two groups: The total effective rate of the Qiliqiangxin group was 84.00%(42/50),higher than the 66.00%(33/50)of the Qishen Yiqi group,with a statistically significant difference(P<0.05).In the subgroup of coronary heart disease,the total effective rate of the Qishen Yiqi group was higher than that of the Qiliqiangxin group,with a statistically significant difference(P<0.05);In the subgroup of dilated heart disease,the total effective rate of treatment in the Qishen Yiqi group was lower than that in the Qiliqiangxin group,with a statistically significant difference(P<0.05).3.Comparison of left ventricular ejection fraction(LVEF)and plasma N-terminal brain natriuretic peptide(NT pro BNP)between the two groups before and after treatment:Before treatment,there was no statistically significant difference in LVEF and serum NT-pro BNP levels between the two groups(P>0.05);After treatment,the LVEF in both groups was higher than before treatment,and the serum NT-pro BNP level in the Qishen Yiqi group was higher than that in the Qiliqiangxin group.The serum NT-pro BNP level in the two groups was lower on average than before treatment,and the Qishen Yiqi group was lower than that in the Qiliqiangxin group,with a statistically significant difference(P<0.05).4.Comparison of left ventricular end diastolic diameter(LVEDD)and left ventricular end systolic diameter(LVESD)between the two groups before and after treatment: Before treatment,there was no statistically significant difference in LVEDD and LVESD levels between the two groups(P>0.05);After treatment,LVEDD and LVESD in both groups were lower than before treatment,and the difference between the Qiliqiangxin group and the Qishen Yiqi group was statistically significant(P<0.05).5.Comparison of serum soluble growth stimulating gene 2 protein(s ST2)expression between the two groups before and after treatment: Before treatment,there was no statistically significant difference in the level of s ST2 between the two groups(P>0.05);After treatment,the levels of s ST2 in both groups were lower than before treatment,and the levels in the Qiliqiangxin group were lower than those in the Qishen Yiqi group,with a statistically significant difference(P<0.05).6.Comparison of the total incidence of adverse reactions and cardiovascular events between the two groups: The total incidence of adverse reactions in the Qiliqiangxin group was 8.00%,while the total incidence of adverse reactions in the Qishen Yiqi group was12.00%;There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).The total incidence of cardiovascular adverse events in the Qishen Yiqi group was 14.00%(7/50),while the total incidence of cardiovascular adverse events in the Qiliqiangxin group was 10.00%(5/50).There was no statistically significant difference in the total incidence of cardiovascular adverse events between the two groups(P>0.05).Conclusions:1.When combined with Entresto in the treatment of HFr EF,Qiliqiangxin capsule is superior in terms of total effective rate and reduction of LVEDD,LVESD,and s ST2.Qishen Yiqi Dropping Pill is superior in improving LVEF and reducing plasma NT-pro BNP levels.2.In patients with HFr EF combined with coronary heart disease,the total effective rate of Qishen Yiqi Dropping Pill combined with Entresto treatment is higher;In patients with HFr EF combined with dilated heart disease,the total effective rate of Qiliqiangxin capsule combined with Entresto treatment is higher.3.The safety of Qiliqiangxin capsule or Qishen Yiqi dropping pill combined with Entresto is good,and there is no significant difference. |
PDF Full Text Request